[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20026011D0 - HMG-CoA-reduktase-inhibitorer og fremgangsmåte - Google Patents

HMG-CoA-reduktase-inhibitorer og fremgangsmåte

Info

Publication number
NO20026011D0
NO20026011D0 NO20026011A NO20026011A NO20026011D0 NO 20026011 D0 NO20026011 D0 NO 20026011D0 NO 20026011 A NO20026011 A NO 20026011A NO 20026011 A NO20026011 A NO 20026011A NO 20026011 D0 NO20026011 D0 NO 20026011D0
Authority
NO
Norway
Prior art keywords
hmg
coa reductase
reductase inhibitors
inhibitors
coa
Prior art date
Application number
NO20026011A
Other languages
English (en)
Other versions
NO20026011L (no
Inventor
Jeffrey A Robl
Bang-Chi Chen
Chong-Qing Sun
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20026011D0 publication Critical patent/NO20026011D0/no
Publication of NO20026011L publication Critical patent/NO20026011L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
NO20026011A 2000-06-15 2002-12-13 HMG-CoA-reduktase-inhibitorer og fremgangsmåte NO20026011L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21159400P 2000-06-15 2000-06-15
PCT/US2001/018868 WO2001096311A2 (en) 2000-06-15 2001-06-12 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases

Publications (2)

Publication Number Publication Date
NO20026011D0 true NO20026011D0 (no) 2002-12-13
NO20026011L NO20026011L (no) 2003-02-12

Family

ID=22787566

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026011A NO20026011L (no) 2000-06-15 2002-12-13 HMG-CoA-reduktase-inhibitorer og fremgangsmåte

Country Status (20)

Country Link
US (1) US20020028826A1 (no)
EP (1) EP1294696A2 (no)
JP (1) JP2004503541A (no)
KR (1) KR20030010720A (no)
CN (1) CN1436174A (no)
AR (1) AR028732A1 (no)
AU (1) AU2001266860A1 (no)
BR (1) BR0111571A (no)
CA (1) CA2412979A1 (no)
CZ (1) CZ20023931A3 (no)
EC (1) ECSP024386A (no)
HU (1) HUP0302955A3 (no)
IL (1) IL152718A0 (no)
MX (1) MXPA02012415A (no)
NO (1) NO20026011L (no)
PE (1) PE20011364A1 (no)
PL (1) PL362477A1 (no)
UY (1) UY26776A1 (no)
WO (1) WO2001096311A2 (no)
ZA (1) ZA200210102B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
HUP0303083A3 (en) * 2000-08-15 2005-05-30 Pfizer Prod Inc Pharmaceutical compositions containing therapeutic combination of a cetp inhibitor and atorvastatin and their use
CZ20033329A3 (cs) * 2001-06-06 2004-11-10 Bristol-Myers Squibb Company Způsob přípravy chirálních sulfondiolů a dihydroxykyselin inhibitorů HMG CoA reduktázy
JP2004536845A (ja) 2001-07-11 2004-12-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療方法
BR0212512A (pt) 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
AU2003248077A1 (en) * 2002-07-18 2004-02-09 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
DE60313339T2 (de) * 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
GB0220885D0 (en) * 2002-09-09 2002-10-16 Novartis Ag Organic compounds
EP1551824B1 (en) * 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
CN101967117A (zh) 2003-05-30 2011-02-09 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg-co抑制剂的用途
US20070161700A1 (en) 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
WO2005087226A1 (en) * 2004-03-05 2005-09-22 Eisai Co., Ltd. Cadasil treatment with cholinesterase inhibitors
AU2005232447A1 (en) * 2004-04-14 2005-10-27 Warner-Lambert Company Llc Therapeutic combination for treatment of Alzheimers disease
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
TW200719916A (en) * 2005-04-12 2007-06-01 Psivida Inc HMGCoA reductase inhibitor combinations and uses thereof
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7498359B2 (en) * 2006-02-07 2009-03-03 Mochida Pharmaceutical., Ltd. Composition and method for preventing recurrence of stroke
CN103217520A (zh) * 2006-02-27 2013-07-24 靶向分子诊断有限责任公司 用于减少细胞脂肪和预测用酪氨酸激酶抑制剂治疗后的心脏毒性的组合物和方法
ES2558799T3 (es) * 2006-03-29 2016-02-08 Kowa Company, Ltd. Agente reductor de triglicéridos y agente de mejora del hiperinsulinismo
WO2008059519A2 (en) * 2006-09-25 2008-05-22 Glenmark Pharmaceuticals Limited A process for the preparation of intermediates of rosuvastatin
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
KR100900044B1 (ko) * 2007-07-05 2009-06-01 한국식품연구원 3-하이드록시-3-메틸글루타릴 보조효소 ａ 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
KR101104335B1 (ko) * 2009-03-06 2012-01-16 가톨릭대학교 산학협력단 알카노일화된 히알루론산으로 형성된 나노입자 및 그 제조방법
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
MX2013000824A (es) * 2010-07-21 2013-10-28 Nucitec Sa De Cv Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico.
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
SI2665722T1 (sl) 2011-01-18 2016-12-30 Dsm Sinochem Pharmaceuticals Netherlands B.V. Postopek priprave diol sulfonov
SI2665721T1 (sl) 2011-01-18 2015-10-30 Dsm Sinochem Pharmaceuticals Netherlands B.V. Metiltetrazol sulfidi in sulfoni
WO2012098049A1 (en) 2011-01-18 2012-07-26 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of statins in the presence of base
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
CA2853804C (en) 2011-10-28 2021-06-01 Vitalis Llc Anti-flush compositions
MX363563B (es) 2011-12-09 2019-03-27 Dsm Sinochem Pharm Nl Bv Proceso para la preparación de un tioprecursor de estatinas.
US8987478B2 (en) 2011-12-09 2015-03-24 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of a statin precursor
WO2013183800A1 (ko) * 2012-06-08 2013-12-12 미래파인켐 주식회사 결정형 ｔ-부틸 2-[（4Ｒ，6Ｓ）-6-포밀-2，2-디메틸-1，3-디옥산-4-일]아세테이트 및 이의 제조 방법
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN112159403B (zh) 2020-09-30 2022-04-15 复旦大学 一种用于合成他汀类药物的关键中间体的制备方法
CN114213350B (zh) * 2021-12-29 2024-03-19 江苏福瑞康泰药业有限公司 一种他汀类药物中间体的制备方法
CN114437052B (zh) * 2021-12-31 2024-03-29 江苏阿尔法集团福瑞药业(宿迁)有限公司 一种利用连续流微通道反应器合成他汀类药物中间体的方法
CN114601039A (zh) * 2022-03-16 2022-06-10 江苏省农业科学院 一种提高热应激下绵羊发情率和受胎率的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
ECSP024386A (es) 2003-03-10
PL362477A1 (en) 2004-11-02
CZ20023931A3 (cs) 2003-03-12
HUP0302955A3 (en) 2005-08-29
PE20011364A1 (es) 2002-02-27
ZA200210102B (en) 2004-03-12
MXPA02012415A (es) 2003-06-06
HUP0302955A2 (hu) 2003-12-29
IL152718A0 (en) 2003-06-24
CN1436174A (zh) 2003-08-13
JP2004503541A (ja) 2004-02-05
US20020028826A1 (en) 2002-03-07
CA2412979A1 (en) 2001-12-20
UY26776A1 (es) 2002-01-31
WO2001096311A2 (en) 2001-12-20
EP1294696A2 (en) 2003-03-26
WO2001096311A3 (en) 2002-07-11
NO20026011L (no) 2003-02-12
AU2001266860A1 (en) 2001-12-24
KR20030010720A (ko) 2003-02-05
AR028732A1 (es) 2003-05-21
BR0111571A (pt) 2003-07-01

Similar Documents

Publication Publication Date Title
NO20026012D0 (no) HMG-CoA-reduktase-inhibitorer og metode
NO20026011D0 (no) HMG-CoA-reduktase-inhibitorer og fremgangsmåte
NO20014823D0 (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
EP1684754A4 (en) HMG COA REDUCTASE INHIBITORS AND METHOD
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
NO20044915L (no) C-aryl-glukosid SGLT2 inhibitorer og metode
NO20024295D0 (no) Cyclopropyl-kondenserte pyrrolidin-baserte inhibitorer av dipeptidyl peptidase IV og fremgangsmåte
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
DK1223918T3 (da) Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor
NO20025416L (no) System og fremgangsmåte ved ekspanderbar komplettering
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
NO20015492D0 (no) Fremgangsmåte og anordning for flersidig forbindelse
DK1339292T3 (da) Sammensætning og fremgangsmåde
NO20052779D0 (no) Doseringsformer omfattende en CETP-inhibitor og en HMG-CoA-reduktaseinhibitor.
NO20040865L (no) Friksjon reduserende sammensetning og metode
NO20026054D0 (no) Akustisk loggeapparat og fremgangsmåte
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
IS6691A (is) Aðferð og algoritmi til að greina mRNA tjáningu
FI20000715A0 (fi) Ryhmätyömenetelmä ja -järjestelmä
DE60135813D1 (de) CDMA Empfangsgerät und -verfahren
AU6045801A (en) Inhibitor function check method and apparatus
DK1307761T3 (da) Fremgangsmåde til retningsbestemmelse og bestemmelsesapparat
AU5258701A (en) Method of searching for arteriosclerosis inhibitors and shrinkers

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application